AbbVie holds a strong portfolio of marketed and pipeline drugs. While the increasing competition to the company's key drug Humira should slow the growth for the company in the near term, we believe the firm's remaining portfolio will mitigate these losses.
AbbVie supports a strong dividend yield, which should act as valuation support, as the cash flows to support the dividend look secure over the next several years.
AbbVie has had to depend on acquisitions to boost its late-stage pipeline, suggesting less successful internal research and development activities.
|
Metric
|
ABBV
|
LLY
|
MRK
|
|---|---|---|---|
Price/Earnings (Normalized) | 15.11 | 88.87 | 84.62 |
Price/Book Value | 28.62 | 65.72 | 8.55 |
Price/Sales | 5.48 | 19.74 | 5.38 |
Price/Cash Flow | 14.86 | 92.33 | 21.26 |
|
Metric
|
ABBV
|
LLY
|
MRK
|
|---|---|---|---|
Quick Ratio | 0.63 | 0.52 | 0.68 |
Current Ratio | 0.87 | 0.94 | 1.25 |
Interest Coverage | 3.57 | 14.13 | 2.33 |
|
Metric
|
ABBV
|
LLY
|
MRK
|
|---|---|---|---|
Return on Assets (Normalized) | 14.54% | 10.22% | 3.59% |
Return on Equity (Normalized) | 150.11% | 52.03% | 9.12% |
Return on Invested Capital (Normalized) | 28.30% | 19.27% | 5.88% |
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
LLY
| Eli Lilly and Co | Kmvjqpmbf | Vcqrm | $695.3 Bil | |
JNJ
| Johnson & Johnson | Scrzqxcm | Rytd | $359.3 Bil | |
MRK
| Merck & Co Inc | Ghdcnrst | Gwgw | $321.5 Bil | |
AZN
| AstraZeneca PLC ADR | Kklbjmlklv | Pvxlm | $215.8 Bil | |
RHHBY
| Roche Holding AG ADR | Jnxyscphj | Jvpv | $203.2 Bil | |
NVS
| Novartis AG ADR | Msnczlyvr | Zsqx | $196.0 Bil | |
PFE
| Pfizer Inc | Xtfkkshfq | Tckn | $148.7 Bil | |
AMGN
| Amgen Inc | Bplphngntp | Cmmj | $145.8 Bil | |
SNY
| Sanofi SA ADR | Tlqvffbq | Cfqyp | $117.3 Bil |
:quality(80)/s3.amazonaws.com/arc-authors/morningstar/a90c659a-a3c5-4ebe-9278-1eabaddc376f.jpg)